DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Bucillamine is an investigational drug.
There have been 4 clinical trials for Bucillamine. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2007.
The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Cystinuria. The leading clinical trial sponsors are Revive Therapeutics, Ltd., Regeneron Pharmaceuticals, and Saitama Medical University.
Recent Clinical Trials for Bucillamine
|Trial in Patients With Cystinuria||Revive Therapeutics, Ltd.||Phase 2|
|Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout||Revive Therapeutics, Ltd.||Phase 2|
|A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)||Regeneron Pharmaceuticals||Phase 3|